Report

Full-year results

Oxford Biodynamics’ EpiSwitch platform has won widespread recognition this year, including a fifth immune-oncology (IO) collaboration and involvement in two clinical trials in ALS and prostate cancer. Its YE’19 financials provided further evidence of ongoing revenue generation whilst investing in increased capacity for additional collaborations, particularly in the IO space. As well as the company gaining the Queen’s Award for Enterprise, EpiSwitch is being used to prospectively identify and measure biomarkers in a partner’s clinical study.
Underlying
Oxford BioDynamics

Provider
Equity Development
Equity Development

​Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.

Analysts
Andy Smith

Other Reports on these Companies
Other Reports from Equity Development

ResearchPool Subscriptions

Get the most out of your insights

Get in touch